Opendata, web and dolomites

Hemstem SIGNED

Targeting leukaemia by modulating hematopoietic stem cell competitiveness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hemstem project word cloud

Explore the words cloud of the Hemstem project. It provides you a very rough idea of what is the project "Hemstem" about.

patient    homing    survive    bm    regulates    surveillance    lecular    chemotherapy    displace    niche    revolutionize    healthy    experimental    crude    hematopoietic    immune    similarity    acute    wnt    lscs    transplantation    allogeneic    ways    devastating    cell    inborn    home    immunotherapy    malignant    hematopoiesis    governing    intensity    surviving    resistance    mutational    paradigm    niches    protective    mo    difficult    subpopulations    severe    affinity    treatments    instead    small    shift    evolutionary    signaling    human    expansion    inhibit    oncogenic    cells    myeloid    conserved    despite    patients    advantages    uses    therapy    molecular    interactions    costly    renewal    bone    30    explores    molecules    hsc    insights    simultaneously    marrow    hscs    visualize    unable    diagnosis    stemness    competitors    vivo    mutations    prove    zebrafish    lsc    profiling    screens    strategies    leukemia    clinical    aml    im    modify    treatment    supporting    fact    wealth    disease    eradicating    curative    rationale    stem    natural    decades    self    leukemic   

Project "Hemstem" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT BASEL 

Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051
website: www.unibas.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 1˙984˙240 €
 EC max contribution 1˙984˙240 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-COG
 Funding Scheme ERC-COG
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2025-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 1˙984˙240.00

Map

 Project objective

Human acute myeloid leukemia (AML) remains a devastating disease with less than 30% of patients surviving five years after diagnosis. Despite decades of research and detailed mo-lecular insights provided by mutational profiling, curative treatment still requires high-intensity chemotherapy and the crude approach of allogeneic stem cell transplantation – an effective, yet non-specific immunotherapy that is costly to the patient because of its severe side effects. One reason why the wealth of molecular and experimental knowledge has so far been unable to revolutionize treatments is the fact that AML is driven by small subpopulations of so-called leukemic stem cells (LSCs), which survive chemotherapy and immune surveillance. LSCs have growth advantages induced by oncogenic mutations, but are in many ways similar to healthy hematopoietic stem cells (HSCs). This similarity makes it difficult to target LSCs without simultaneously eradicating HSCs and healthy hematopoiesis derived from these cells. Like HSCs, LSCs home to protective bone marrow (BM) niches promoting stemness and therapy resistance and modify them to displace HSCs and promote their own expansion. This proposal explores strategies to target LSCs based on understanding these interactions. In Aim 1 we investigate how WNT signaling, an evolutionary conserved pathway governing stem cell self-renewal, regulates interactions between leukemic and healthy hematopoietic (stem) cells. In Aim 2, we propose to inhibit the in vivo expansion of LSCs by enhancing self-renewal and niche affinity in their natural competitors, the healthy stem cells with inborn BM homing ability. Aim 3 uses zebrafish to visualize LSC-HSC interactions and screens for molecules supporting healthy instead of (pre-) malignant hematopoiesis. Our studies will im-prove the knowledge on the complex interactions between LSCs and HSCs and provide a rationale for novel treatments that might lead to a paradigm-shift in the clinical management of AML.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEMSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More